Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules)

OBJECTIVE: In the REPLENISH trial, women receiving TX-001HR—an oral, softgel capsule, combining 17β-estradiol (E2) and progesterone (E2 mg/P4 mg 1/100, 0.5/100), had significantly improved vasomotor symptoms, while having their endometrium protected from hyperplasia. The objective here was to descri...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Menopause
Autores principales: Lobo, Rogerio A., Liu, James, Stanczyk, Frank Z., Constantine, Ginger D., Pickar, James H., Shadiack, Annette M., Bernick, Brian, Mirkin, Sebastian
Formato: Artigo
Lenguaje:Inglês
Publicado: Lippincott-Raven Publishers 2019
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6636803/
https://ncbi.nlm.nih.gov/pubmed/30694918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/GME.0000000000001306
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares